All posts from Zacks
Zacks in Our Research. Your Success.,

BioDelivery (BDSI) Posts In-Line Loss in Q1, Revenues Miss

BioDelivery Sciences International, Inc. BDSI reported a loss of 36 cents per share in the first quarter of 2016, in-line with the Zacks Consensus Estimate but wider than the year-ago loss of 16 cents per share.

First-quarter 2016 revenues declined 76.7% from the year-ago period to $3.04 million, just shy of the Zacks Consensus Estimate of $3.07 million.

BioDelivery’s opioid-dependence drug, Bunavail, registered sales of $2.1 million, up 40% sequentially. However, prescriptions slipped 4% sequentially – the company said that the sequential decline was consistent with the decline in prescriptions for the overall market. The prescriber base expanded to 3,000 with 350 unique prescribers added during the first quarter of 2016.

Meanwhile, Belbuca was launched in the U.S. on Feb 22, 2016. Although BioDelivery’s commercial partner, Endo International plc ENDP said that early healthcare provider feedback is positive, the first few weeks of sales were slower than expected.

Reducing Bunavail Spend

With Bunavail’s sales trajectory not yielding desired results, BioDelivery announced that it is taking decisive actions to better align costs with revenue and reduce spending.  

The company plans to strategically consolidate the sales force so that efforts are focused on the most productive territories. Marketing spend will also be reduced and will lead to total savings of about $20 million by the end of 2017. The company will end its contract sales agreement with Quintiles as well.   

The company is also planning a highly targeted Bunavail-focused, direct-to-patient digital advertising campaign – results from this campaign will be evaluated in the third quarter.

Our Take

BioDelivery’s first-quarter results were disappointing. Bunavail’s performance continues to lag and the company is now taking steps to reduce spend on the product and focus on the most productive territories. Belbuca is also off to a disappointing start with Endo expecting an inflection point sometime in the second half of the year.

BioDelivery is a Zacks Rank #3 (Hold) stock. ArQule Inc. ARQL and BioSpecifics Technologies Corp. BSTC are some better-ranked stocks in the health care sector, each carrying a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. blog">Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
BIODELIVERY SCI (BDSI): Free Stock Analysis Report
ENDO INTL PLC (ENDP): Free Stock Analysis Report
BIOSPECIFICS TE (BSTC): Free Stock Analysis Report
ARQULE INC (ARQL): Free Stock Analysis Report
To read this article on click here.
Zacks Investment Research